Etiology Analysis of Chronic Cough After COVID-19 Infection and Research on the Efficacy of ICS or ICS/LABA

Status

Enrolling by invitation

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06503939

Enrollment

600

Registered

2024-07-16

Start date

2023-09-01

Completion date

2024-12-31

Last updated

2024-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Cough

Keywords

COVID-19

Brief summary

This study collected 600 patients, evaluated whether patients had airway hyperreactivity, airway inflammation, specific types and allergic reactions, comprehensively analyzed and classified the causes of chronic cough in patients, and evaluated and compared the improvement of cough symptoms and quality of life after ICS or ICS/LABA treatment.

Detailed description

The subjects of this study were patients with chronic cough who were admitted to the Department of Respiratory and Critical Care Medicine, Xiangya Hospital, Central South University from September 1, 2023 to December 31, 2024. Patients are registered if they meet all of the following criteria: (1) ≥18 years of age; (2) A clear history of COVID-19 infection with a positive nucleic acid or antigen test before chronic cough;(3) Persistent cough for more than 8 weeks after the acute phase of COVID-19 infection has disappeared; (4) Chest X-ray and/or chest CT without significant evidence of lung disease; (5) No history of chronic cough (\>8 weeks) prior to COVID-19 infection. Patients who met any of the following criteria were excluded: (1) Patients refused pulmonary function, blood tests; (2) The patient has previously been diagnosed with respiratory diseases with cough as one of the main symptoms, including cough variant asthma, allergic bronchitis, eosinophilic bronchitis, gastroesophageal reflux disease, chronic obstructive pulmonary disease, chronic bronchitis, bronchiectasis, interstitial lung disease, pulmonary/tracheobronchial tuberculosis, etc.; (3) Patients who are pregnant or breastfeeding; (4) The patient's medical records are incomplete; (5) Patients lost to follow-up.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Age ≥18 years old; 2. A clear history of COVID-19 infection with a positive nucleic acid or antigen test before chronic cough; 3. Persistent cough for more than 8 weeks after the acute phase of COVID-19 infection has disappeared; 4. Chest X-ray and/or chest CT without significant evidence of lung disease; 5. No history of chronic cough (\>8 weeks) prior to COVID-19 infection.

Exclusion criteria

1. The patient refused pulmonary function and blood tests; 2. The patient has previously been diagnosed with respiratory diseases with cough as one of the main symptoms, including cough variant asthma, allergic bronchitis, eosinophilic bronchitis, gastroesophageal reflux disease, chronic obstructive pulmonary disease, chronic bronchitis, bronchiectasis, interstitial lung disease, pulmonary/tracheobronchial tuberculosis, etc.; 3. Patients who are pregnant or breastfeeding; 4. The patient's medical records are incomplete; 5. Patients lost to follow-up.

Design outcomes

Primary

Measure	Time frame
The etiology of chronic cough was comprehensively analyzed and classified.	2023.09-2024.12

Secondary

Measure	Time frame
To evaluate and compare cough symptoms and quality of life improvement after ICS or ICS/LABA treatment.	2023.09-2024.12

Countries

China

Outcome results